These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 10464383)
21. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features. Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973 [TBL] [Abstract][Full Text] [Related]
22. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. Sanchez JA; Dejulius KL; Bronner M; Church JM; Kalady MF Inflamm Bowel Dis; 2011 Sep; 17(9):1966-70. PubMed ID: 21618350 [TBL] [Abstract][Full Text] [Related]
23. Molecular alterations in chronic ulcerative colitis-associated and sporadic hyperplastic polyps: a comparative analysis. Odze RD; Brien T; Brown CA; Hartman CJ; Wellman A; Fogt F Am J Gastroenterol; 2002 May; 97(5):1235-42. PubMed ID: 12014733 [TBL] [Abstract][Full Text] [Related]
24. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: immunohistochemical study. Ajioka Y; Watanabe H; Matsuda K J Gastroenterol; 1995 Nov; 30 Suppl 8():33-5. PubMed ID: 8563884 [TBL] [Abstract][Full Text] [Related]
25. K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Chaubert P; Benhattar J; Saraga E; Costa J Am J Pathol; 1994 Apr; 144(4):767-75. PubMed ID: 8160776 [TBL] [Abstract][Full Text] [Related]
26. Comparison of p53 immunoexpression with allelic loss of p53 in ulcerative colitis-associated dysplasia and carcinoma. Fogt F; Zhuang Z; Poremba C; Dockhorn-Dworniczak B; Vortmeyer A Oncol Rep; 1998; 5(2):477-80. PubMed ID: 9468583 [TBL] [Abstract][Full Text] [Related]
27. DPC4 gene mutation in colitis associated neoplasia. Hoque AT; Hahn SA; Schutte M; Kern SE Gut; 1997 Jan; 40(1):120-2. PubMed ID: 9155588 [TBL] [Abstract][Full Text] [Related]
29. Who takes the lead in the development of ulcerative colitis-associated colorectal cancers: mutator, suppressor, or methylator pathway? Maia L; Dinis J; Cravo M; Claro I; Baltazar C; Fonseca I; Veloso T; Capelinha AF; Carneiro F; Nobre-Leitão C Cancer Genet Cytogenet; 2005 Oct; 162(1):68-73. PubMed ID: 16157203 [TBL] [Abstract][Full Text] [Related]
30. p53 mutations in solar keratoses. Park WS; Lee HK; Lee JY; Yoo NJ; Kim CS; Kim SH Hum Pathol; 1996 Nov; 27(11):1180-4. PubMed ID: 8912828 [TBL] [Abstract][Full Text] [Related]
31. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi Y; Dohi K; Nakamura N; Akiyama M Jpn J Cancer Res; 1993 May; 84(5):526-31. PubMed ID: 8100564 [TBL] [Abstract][Full Text] [Related]
32. Screening for dysplasia and TP53 mutations in closed rectal stumps of patients with ulcerative colitis or Crohn disease. Winther KV; Bruun E; Federspiel B; Guldberg P; Binder V; Brynskov J Scand J Gastroenterol; 2004 Mar; 39(3):232-7. PubMed ID: 15074392 [TBL] [Abstract][Full Text] [Related]
33. Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis. Lashner BA; Bauer WM; Rybicki LA; Goldblum JR Am J Gastroenterol; 2003 Jun; 98(6):1423-7. PubMed ID: 12818291 [TBL] [Abstract][Full Text] [Related]
34. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer. Friedrich MG; Erbersdobler A; Schwaibold H; Conrad S; Huland E; Huland H J Urol; 2000 Mar; 163(3):1039-42. PubMed ID: 10688045 [TBL] [Abstract][Full Text] [Related]
35. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC). Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782 [TBL] [Abstract][Full Text] [Related]
36. Cancer biology in ulcerative colitis and potential use in endoscopic surveillance. Shapiro BD; Lashner BA Gastrointest Endosc Clin N Am; 1997 Jul; 7(3):453-68. PubMed ID: 9177146 [TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity of the retinoblastoma and p53 genes in primary cervical carcinomas with human papillomavirus infection. Kim JW; Lee CG; Han SM; Kim KS; Kim JO; Lee JM; Kim IK; Namkoong SE Gynecol Oncol; 1997 Nov; 67(2):215-21. PubMed ID: 9367711 [TBL] [Abstract][Full Text] [Related]
38. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers. Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283 [TBL] [Abstract][Full Text] [Related]
39. Upregulation of p16(INK4A) and Bax in p53 wild/p53-overexpressing crypts in ulcerative colitis-associated tumours. Yoshida T; Matsumoto N; Mikami T; Okayasu I Br J Cancer; 2004 Sep; 91(6):1081-8. PubMed ID: 15292938 [TBL] [Abstract][Full Text] [Related]
40. Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. Meltzer SJ; Mane SM; Wood PK; Resau JH; Newkirk C; Terzakis JA; Korelitz BI; Weinstein WM; Needleman SW Cancer Res; 1990 Jun; 50(12):3627-30. PubMed ID: 2187599 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]